Long-term disease control by endobiliary radiofrequency ablation in localized extrahepatic cholangiocarcinoma: a first case report

Clin J Gastroenterol. 2023 Dec;16(6):908-912. doi: 10.1007/s12328-023-01845-3. Epub 2023 Aug 24.

Abstract

An 84-year-old woman with cerebrovascular disease, dementia, and chronic kidney disease developed jaundice because of localized extrahepatic cholangiocarcinoma (eCCA) at the lower bile duct. Aggressive treatment, including surgery and chemotherapy, was difficult because of the underlying disease; therefore, only metal stent placement with endobiliary radiofrequency ablation (RFA) was performed. Subsequently, six additional RFA sessions were performed 12, 16, 24, 27, 33, and 36 months after the initial RFA using the same settings as the first RFA session. All these procedures were performed for tumor ingrowth. Computed tomography performed 42 months after the initial procedure revealed no stent with stricture resolution and no other metastatic lesion. Thereafter, no recurrence or adverse events have been observed with persisting stent-free status until the reporting of this study (72 months after the initial procedure). This is the first report of a stent-free status and long-term survival in a patient with localized eCCA that was achieved using only endobiliary RFA without any other anti-tumor treatment. Although several problems and issues associated with endobiliary RFA remain unelucidated, it may be a useful therapeutic option for early and localized eCCA in poor surgical candidates.

Keywords: Bile duct stricture; Biliary stent; Endobiliary radiofrequency ablation; Extrahepatic cholangiocarcinoma.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Bile Duct Neoplasms* / complications
  • Bile Ducts, Intrahepatic / pathology
  • Catheter Ablation* / adverse effects
  • Cholangiocarcinoma* / surgery
  • Cholestasis* / etiology
  • Female
  • Humans
  • Radiofrequency Ablation* / adverse effects
  • Stents / adverse effects
  • Treatment Outcome